Maribavir for cytomegalovirus infection after stem cell transplant
Treatments studied
Part of Infections clinical trials.
This study tests a medicine called maribavir for people who have a cytomegalovirus infection after a stem cell transplant. It aims to see if the drug safely clears the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell transplant.
- You have a confirmed cytomegalovirus (CMV) infection, either in your blood or in a specific organ.
- Doctors expect you to live for at least another 4 weeks.
- Your liver function tests are not severely elevated (AST and ALT not more than 5 times the upper limit of normal, and total bilirubin below 3 times the upper limit).
- You are not currently participating in another CMV-related clinical trial.
- You are mentally able to understand the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This trial tests whether taking maribavir for different lengths of time can help treat a stubborn CMV infection after a stem cell transplant. It is for people whose CMV hasn't improved with standard treatment.
This study looks at the medication maribavir for people who have a CMV infection after a transplant that is not getting better with current treatments. The goal is to see how well maribavir works in this situation.
This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.
This study looks at how well the drug maribavir works in adults with kidney failure who get a CMV infection after a transplant. It focuses on people whose CMV infection hasn't responded to other treatments.
This trial tests a new drug, maribavir, for controlling or treating active CMV infection in people with certain blood cancers (multiple myeloma, follicular lymphoma, or large B-cell lymphoma) who are taking a bispecific antibody therapy. The goal is to see if maribavir is safe and effective for managing CMV in this specific situation.
Hear when a new Infections, Cytomegalovirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.